Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 29;9(1):237-245.
doi: 10.1080/22221751.2020.1717380. eCollection 2020.

Colistin-resistance gene mcr in clinical carbapenem-resistant Enterobacteriaceae strains in China, 2014-2019

Affiliations

Colistin-resistance gene mcr in clinical carbapenem-resistant Enterobacteriaceae strains in China, 2014-2019

Hong Huang et al. Emerg Microbes Infect. .

Abstract

To investigate whether introduction of colistin into the clinical settings selected colistin-resistant CRE, we performed molecular epidemiological study of 1868 CRE strains collected from different geographical locales in China during the period 2014-2019. 1755 (96.18%) isolates carried the carbapenemase genes blaKPC and blaNDM; 14 Escherichia coli isolates (0.75%) carrying mcr-1 and blaNDM (MCR-CREC) were also identified. Importantly, the number and relative prevalence of MCR-CREC isolates increased from 5 (0.41%) to 9 (1.38%) after introduction of polymyxin into clinical practice. Consistently, results of genetic analysis indicated that MCR-CREC strains collected before December 2017 were genetically diverse, yet those collected after that date exhibited more closely related genetic profiles, indicating that specific MCR-CREC strains were rapidly selected as a result of increased usage of colistin in clinical settings. The resistance level of MCR-CREC isolates to colistin increased after the introduction of polymyxin into clinical use with the MIC to colistin from <2 mg/L in 80% strains to 2 mg/L in 100% strains. Further dissemination of MCR-CREC strains, which exhibit resistance to the last-line drugs of carbapenems and colistin, is expected to pose a severe threat to human health.

Keywords: Carbapenem-resistant Enterobacteriaceae; China; clinical uses; colistin; mcr-1.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the authors.

Figures

Figure 1.
Figure 1.
Distribution of mcr-1 in carbapenem-resistant Enterobacteriaceae strains in China. mcr-1-producing isolates were denoted with stars. The provinces included in this study are shaded.
Figure 2.
Figure 2.
Mid-point rooted phylogeny of mcr-1-bearing E. coli strains. (A) Strains isolated before 1 December 2017 were labelled with grey backgrounds. MLST, O and H serotypes, the presence of antimicrobial resistance genes (AMR) encoding ESBLs, carbapenemases, and MCR-1 were plotted. Year of isolation for each strain was denoted after the dash line.

Similar articles

Cited by

References

    1. Logan LK, Weinstein RA.. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215(suppl_1):S28–S36. - PMC - PubMed
    1. Zhang R, Liu L, Zhou H, et al. . Nationwide surveillance of clinical carbapenem-resistant Enterobacteriaceae (CRE) strains in China. EBioMedicine. 2017;19:98–106. - PMC - PubMed
    1. Zhang Y, Wang Q, Yin Y, et al. . Epidemiology of carbapenem-resistant Enterobacteriaceae infections: report from the China CRE Network. Antimicrob Agents Chemother. 2018;62(2):e01882–17. - PMC - PubMed
    1. Hu F-P, Guo Y, Zhu DM, et al. . Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005–2014. Clin Microbiol Infect. 2016;22:S9–S14. - PubMed
    1. Nordmann P, Dortet L, Poirel L.. Carbapenem resistance in Enterobacteriaceae: here is the storm!. Trends Mol Med. 2012;18(5):263–272. - PubMed

MeSH terms